Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sabatolimab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...
Sabatolimab by Novartis for Myelofibrosis: Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs...
Sabatolimab by Novartis for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase II for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to GlobalData,...
Sabatolimab by Novartis for Glioblastoma Multiforme (GBM): Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
Sabatolimab by Novartis for Gliosarcoma: Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs...
Sabatolimab by Novartis for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Sabatolimab is under clinical development by Novartis and currently in Phase III for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Novartis's Sabatolimab?
Sabatolimab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Chronic Myelomonocytic Leukemia (CMML). According...